Published in Kidney Int on February 01, 2005
The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol (2008) 1.76
Calcimimetic inhibits late-stage cyst growth in ADPKD. J Am Soc Nephrol (2009) 1.58
Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol (2009) 1.51
Phosphate control in end-stage renal disease: barriers and opportunities. Nephrol Dial Transplant (2013) 1.46
Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol (2008) 1.36
Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clin J Am Soc Nephrol (2009) 1.04
Surgical management of secondary hyperparathyroidism in chronic kidney disease-a consensus report of the European Society of Endocrine Surgeons. Langenbecks Arch Surg (2015) 1.03
Parathyroidectomy for the attainment of NKF-K/DOQI™ and KDIGO recommended values for bone and mineral metabolism in dialysis patients with uncontrollable secondary hyperparathyroidism. Langenbecks Arch Surg (2012) 1.02
Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study. Clin J Am Soc Nephrol (2012) 0.96
The surgical management of renal hyperparathyroidism. Eur Arch Otorhinolaryngol (2011) 0.91
Middle-term use of Cinacalcet in paediatric dialysis patients. Pediatr Nephrol (2009) 0.89
The role of bone biopsy in patients with chronic renal failure. Clin J Am Soc Nephrol (2008) 0.89
Current trends in surgery for renal hyperparathyroidism (RHPT)--an international survey. Langenbecks Arch Surg (2012) 0.89
An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects. Pediatr Nephrol (2012) 0.87
Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns. Clin J Am Soc Nephrol (2011) 0.86
Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism. NDT Plus (2008) 0.83
Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism. Clin J Am Soc Nephrol (2015) 0.81
CKD-MBD: impact on management of kidney disease. Clin Exp Nephrol (2007) 0.80
The effects of discontinuing cinacalcet at the time of kidney transplantation. NDT Plus (2009) 0.80
Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism. Int J Nephrol Renovasc Dis (2013) 0.79
In vivo regeneration of renal vessels post whole decellularized kidneys transplantation. Oncotarget (2015) 0.79
A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. Transplantation (2016) 0.79
A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol (2015) 0.79
Hyperphosphatemia Management in Patients with Chronic Kidney Disease. Saudi Pharm J (2015) 0.79
Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis. Clin J Am Soc Nephrol (2017) 0.78
Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review. Clin Cases Miner Bone Metab (2009) 0.78
Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism. Clin Exp Nephrol (2011) 0.78
Parathyroidectomy Is Associated with Reduced Mortality in Hemodialysis Patients with Secondary Hyperparathyroidism. Biomed Res Int (2015) 0.78
Calcimimetics in CKD-results from recent clinical studies. Pediatr Nephrol (2008) 0.78
Potential future uses of calcimimetics in patients with chronic kidney disease. NDT Plus (2008) 0.77
Clinical outcomes in secondary hyperparathyroidism and the potential role of calcimimetics. NDT Plus (2008) 0.76
Rapid decrease of intact parathyroid hormone could be a predictor of better response to cinacalcet in hemodialysis patients. Yonsei Med J (2013) 0.76
Cinacalcet in pediatric and adolescent chronic kidney disease: a single-center experience. Medicine (Baltimore) (2015) 0.75
Rates of Intentional and Unintentional Nonadherence to Peritoneal Dialysis Regimes and Associated Factors. PLoS One (2016) 0.75
A new paradigm for the treatment of secondary hyperparathyroidism. NDT Plus (2008) 0.75
Clinical significance of parathyroid intervention on CKD-MBD management. NDT Plus (2008) 0.75
Efficacy of early treatment with calcimimetics in combination with reduced doses of vitamin d sterols in dialysis patients. NDT Plus (2008) 0.75
Risk factors associated with secondary hyperparathyroidism in patients with chronic kidney disease. Exp Ther Med (2016) 0.75
Long-Term Hypoparathyroidism and Hypophosphatemia in Dialysis Patients. J Investig Med High Impact Case Rep (2014) 0.75
Efficacy of low-dose cinacalcet on alternate days for the treatment of secondary hyperparathyroidism in hemodialysis patients: a single-center study. Int J Nephrol Renovasc Dis (2017) 0.75
Achievement of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative: recommended serum calcium, phosphate and parathyroid hormone values with parathyroidectomy in patients with secondary hyperparathyroidism. J Korean Surg Soc (2013) 0.75
Trajectories of CKD-MBD biochemical parameters over a 2-year period following diagnosis of secondary hyperparathyroidism: a pharmacoepidemiological study. BMJ Open (2017) 0.75
Cinacalcet in hyperparathyroidism management after pediatric renal transplantation. CEN Case Rep (2016) 0.75
Cinacalcet: the chemical parathyroidectomy? Clin Kidney J (2013) 0.75
Monitoring of hemodialysis quality-of-care indicators: why is it important? BMC Nephrol (2013) 0.75
Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis. PLoS One (2016) 0.75
A computerized treatment algorithm trial to optimize mineral metabolism in ESRD. Clin J Am Soc Nephrol (2012) 0.75
Secondary hyperparathyroidism disease stabilization following calcimimetic therapy. NDT Plus (2008) 0.75
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med (2004) 49.19
Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med (2008) 14.40
Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med (2010) 12.04
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol (2004) 11.23
In-center hemodialysis six times per week versus three times per week. N Engl J Med (2010) 10.73
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med (2012) 8.88
The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol (2003) 7.79
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet (2006) 7.53
Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA (2002) 7.20
Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol (2006) 6.66
Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol (2004) 6.59
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med (2004) 6.52
Functional status of elderly adults before and after initiation of dialysis. N Engl J Med (2009) 6.45
Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int (2004) 6.04
Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int (2009) 5.28
Predialysis nephrology care of older patients approaching end-stage renal disease. Arch Intern Med (2011) 5.11
Validity of International Classification of Diseases, Ninth Revision, Clinical Modification Codes for Acute Renal Failure. J Am Soc Nephrol (2006) 4.95
Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int (2009) 4.72
The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int (2011) 4.27
Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol (2005) 3.96
Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol (2008) 3.93
Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med (2002) 3.92
Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol (2002) 3.83
Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Ann Intern Med (2013) 3.83
Octogenarians and nonagenarians starting dialysis in the United States. Ann Intern Med (2007) 3.80
Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med (2009) 3.69
Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab (2006) 3.57
Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol (2006) 3.36
Nonrecovery of kidney function and death after acute on chronic renal failure. Clin J Am Soc Nephrol (2009) 3.28
Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int (2005) 3.22
Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. J Am Soc Nephrol (2005) 3.14
The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant (2010) 3.10
Nephrology consultation in acute renal failure: does timing matter? Am J Med (2002) 2.95
Effects of phosphate binders in moderate CKD. J Am Soc Nephrol (2012) 2.92
How fibroblast growth factor 23 works. J Am Soc Nephrol (2007) 2.92
Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol (2005) 2.91
Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem (2003) 2.91
Acute renal failure definitions and classification: time for change? J Am Soc Nephrol (2003) 2.81
Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study. Ann Intern Med (2013) 2.74
Refining predictive models in critically ill patients with acute renal failure. J Am Soc Nephrol (2002) 2.74
Significance of frailty among dialysis patients. J Am Soc Nephrol (2007) 2.62
Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation (2006) 2.61
An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health (2009) 2.60
Timing of initiation of dialysis in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol (2006) 2.56
Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol (2005) 2.55
Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int (2005) 2.54
Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int (2004) 2.52
Fluid accumulation, recognition and staging of acute kidney injury in critically-ill patients. Crit Care (2010) 2.51
Cognitive impairment in chronic kidney disease. J Am Geriatr Soc (2004) 2.50
Frailty and chronic kidney disease: the Third National Health and Nutrition Evaluation Survey. Am J Med (2009) 2.39
The case against calcium-based phosphate binders. Clin J Am Soc Nephrol (2006) 2.38
Parathyroidectomy rates among United States dialysis patients: 1990-1999. Kidney Int (2004) 2.37
Association of body size with outcomes among patients beginning dialysis. Am J Clin Nutr (2004) 2.37
Weekend hospital admission, acute kidney injury, and mortality. J Am Soc Nephrol (2010) 2.30
Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease. J Am Soc Nephrol (2006) 2.26
Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study. Circulation (2007) 2.23
Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol (2004) 2.21
Longitudinal study of nutritional status, body composition, and physical function in hemodialysis patients. Am J Clin Nutr (2003) 2.19
The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol (2002) 2.18
Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol (2007) 2.16
Effect of frequent hemodialysis on residual kidney function. Kidney Int (2013) 2.10
Frailty, dialysis initiation, and mortality in end-stage renal disease. Arch Intern Med (2012) 2.10
Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res (2003) 2.05
Chronic kidney disease and functional limitation in older people: health, aging and body composition study. J Am Geriatr Soc (2006) 2.04
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis (2008) 2.02
Risk of cardiovascular events after infection-related hospitalizations in older patients on dialysis. Clin J Am Soc Nephrol (2011) 2.02
Sepsis as a cause and consequence of acute kidney injury: Program to Improve Care in Acute Renal Disease. Intensive Care Med (2010) 2.00
Acute kidney injury and mortality in hospitalized patients. Am J Nephrol (2012) 1.99
Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev (2012) 1.97
Methodological issues in studying the epidemiology of mild to moderate chronic renal insufficiency. Kidney Int (2002) 1.96
KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis (2010) 1.93
Control of hypertension in adults with chronic kidney disease in the United States. Hypertension (2005) 1.92
Dialysate sodium and sodium gradient in maintenance hemodialysis: a neglected sodium restriction approach? Nephrol Dial Transplant (2011) 1.92
Chronic kidney disease and cognitive impairment in menopausal women. Am J Kidney Dis (2005) 1.91
Cystatin C and measures of physical function in elderly adults: the Health, Aging, and Body Composition (HABC) Study. Am J Epidemiol (2006) 1.91
Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology. Clin J Am Soc Nephrol (2012) 1.90
PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis (2006) 1.86
Identification of a novel extracellular cation-sensing G-protein-coupled receptor. J Biol Chem (2005) 1.86
Burden on caregivers as perceived by hemodialysis patients in the Frequent Hemodialysis Network (FHN) trials. Nephrol Dial Transplant (2011) 1.85
Shorter dialysis times are associated with higher mortality among incident hemodialysis patients. Kidney Int (2010) 1.83
The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int (2003) 1.82
Correlates and outcomes of dementia among dialysis patients: the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant (2006) 1.82
Vascular calcification in chronic kidney disease. Am J Kidney Dis (2004) 1.81
Nutritional status in dialysis patients: a European consensus. Nephrol Dial Transplant (2002) 1.81
Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant (2008) 1.81